Project Grant R03AG087485
Award Date
6/1/25
Completion Date
5/31/27
Dollars Obligated
$303K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This federal Project Grant award of $528,876.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to Emory University will support a 5-year research study to investigate the genetic regulation of brain transcriptomics and proteomics associated with Alzheimer's disease and related dementias (AD/ADRD). The key objectives are to: Estimate genome-wide cis- and trans-acting quantitative trait loci (QTLs) for transcriptome-wide genes and proteome-wide proteins across multiple brain...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,559,999 to the Regents of the University of Michigan to conduct a comprehensive study on the APOE gene and the noncoding RNA AANCR to advance Alzheimer's disease treatment. The research aims to elucidate how AANCR regulates APOE transcription and how AANCR is modulated to maintain cell-type specific and stress-induced APOE expression. The project will also assess the effects of APOE...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,104,254 to the HudsonAlpha Institute for Biotechnology to identify transcription factors that regulate the expression of the MAPT gene, which is associated with neurodegenerative diseases like Alzheimer's. The key objectives are to: 1) Use CRISPR-based screens to find transcription factors that can modulate MAPT transcription, 2) Determine which trans-regulatory elements directly interact...
This federal Project Grant award for $310,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research at Texas Tech University Health Sciences Center (TTUHSC) to examine the role of alternative polyadenylation (APA) of mRNAs in the development and progression of Alzheimer's disease (AD). The key goals are to: 1) Identify APA genes and pathways associated with AD pathology using computational analysis of existing single-cell RNA sequencing datasets, and 2)...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $619,681 to The Leland Stanford Junior University will support the development of "Combo-Seq/Tag", a toolkit combining gene editing and protein tagging technologies. The goal is to efficiently perturb Alzheimer's disease (AD) risk genes and conduct multi-omics analyses in human stem cell and in vivo mouse models. The award will yield innovative gene editing vectors...
This federal Project Grant award of $1,205,827.00 was provided by the National Institute on Aging (NIA) under CFDA Program 93.866 - Aging Research. The award, with a start date of August 1, 2024 and ultimate completion date of June 30, 2029, will support a study examining the role of the "exposome" (environmental exposures) as a risk factor for Alzheimer's disease among diverse racial/ethnic populations. The project will utilize blood samples from 3,000 participants in the ongoing...
This Project Grant from the National Institutes of Health's National Institute on Aging, under the Aging Research program (CFDA 93.866), provides $4,041,438 to develop new computational tools and biomarkers for Alzheimer's disease. The University of Miami will aggregate and analyze DNA methylation datasets to identify age-associated epigenetic changes related to aging and Alzheimer's progression. Researchers will create a searchable web interface to disseminate findings on the role of DNA...
This Project Grant award, valued at $802,034 and funded by the National Institute on Aging's Aging Research program (CFDA 93.866), aims to develop a comprehensive "multimodal, multiscale and multistage systems biology (M3SB) infrastructure" to advance precision medicine for Alzheimer's disease (AD) and longevity research. The key objectives are to: 1) conduct multi-omics analyses to identify bioage-modifying targets and repurposable medicines for AD and related dementias; 2) build...
This Project Grant award, funded by the National Institute on Aging (CFDA 93.866 - Aging Research), aims to develop high-performing, fair, and interpretable large language models (LLMs) to detect Alzheimer's disease (AD) and its precursor stages, Mild Cognitive Impairment (MCI), from transcribed unstructured speech samples. The $300,506 award, effective from Aug 1, 2024 to May 31, 2028, will test the use of fair and explainable LLMs to identify early stages of the AD trajectory, focusing on...
This $466,125 Project Grant award, funded by the National Institute on Aging under the Aging Research program (CFDA 93.866), supports research to investigate the effects of Alzheimer's disease (AD) on subcellular transcriptome dynamics and mitochondrial-nuclear (mitonuclear) coordination in neurons. The primary awardee, President and Fellows of Harvard College (doing business as Harvard Medical School), will adapt a novel RNA-flow analysis technique (STL-SEQ) to quantify transcription, nuclear...